JNJ-70218902

N/A

Report date: 2026/03/19 17:12:22

Base Information

Drug NameJNJ-70218902

Drug Alias NameJNJ-70218902

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUkraine +[13]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[7]

Inactive IndicationsN/A

Other Information

ATC CodeN/A